Key Points
- CFO Brian Piekos sold 1,862 shares of KalVista on April 17 at an average price of $20.22 for $37,649.64 to cover tax withholding on vested awards, leaving him with 18,150 shares (a 9.3% reduction).
- Multiple insiders, including CEO Benjamin Palleiko (9,550 shares), also sold shares on April 17; filings say the sales were for tax obligations but the concentrated insider selling could exert short‑term downward pressure.
- Despite the insider sales, institutional buying and analyst positivity persist — the company has strong liquidity (current/quick ratios ≈7.2), a market cap of about $1.07B, and a consensus analyst price target of $32.60 (seven Buys vs. one Sell).
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CFO Brian Piekos sold 1,862 shares of the company's stock in a transaction that occurred on Friday, April 17th. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64. Following the completion of the transaction, the chief financial officer owned 18,150 shares in the company, valued at approximately $366,993. This represents a 9.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Brian Piekos also recently made the following trade(s):
- On Monday, February 23rd, Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $15.57, for a total value of $27,512.19.
KalVista Pharmaceuticals Stock Performance
Shares of KALV stock opened at $20.87 on Tuesday. The firm has a market capitalization of $1.07 billion, a PE ratio of -5.28 and a beta of -0.40. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.83 and a 52 week high of $21.31. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The company has a 50 day moving average price of $17.50 and a 200-day moving average price of $15.23.
Key KalVista Pharmaceuticals News
Here are the key news stories impacting KalVista Pharmaceuticals this week:
- Positive Sentiment: Several sell‑side firms have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), and recent filings show large institutional stakes being established or increased — a combination that supports upward momentum and a consensus target materially above the current price. MarketBeat coverage
- Neutral Sentiment: Company fundamentals and technicals offer context: market cap ≈ $1.07B, very strong liquidity (current and quick ratios ≈7.2) and the 50‑day / 200‑day moving averages ($17.50 / $15.23) sit below the current trade — supportive background but not an immediate catalyst for price moves.
- Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares at ~$20.22; CFO Brian Piekos and other insiders also sold smaller blocks). Filings say sales were to cover tax withholding on vested awards, but concentrated insider selling can still create short‑term downward pressure or investor concern. InsiderTrades alert
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in shares of KalVista Pharmaceuticals by 3.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company's stock valued at $30,464,000 after buying an additional 88,720 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $24,360,000. State Street Corp lifted its stake in shares of KalVista Pharmaceuticals by 21.3% during the 4th quarter. State Street Corp now owns 1,911,691 shares of the specialty pharmaceutical company's stock valued at $30,874,000 after buying an additional 336,195 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of KalVista Pharmaceuticals by 152.0% during the 4th quarter. Vestal Point Capital LP now owns 1,890,000 shares of the specialty pharmaceutical company's stock valued at $30,524,000 after buying an additional 1,140,000 shares in the last quarter. Finally, Parkman Healthcare Partners LLC lifted its stake in shares of KalVista Pharmaceuticals by 155.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company's stock valued at $21,132,000 after buying an additional 1,055,940 shares in the last quarter.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Stifel Nicolaus increased their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Thursday, March 26th. Citizens Jmp lowered their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a research note on Thursday, March 26th. HC Wainwright increased their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a "buy" rating in a research note on Friday, January 9th. Finally, Wall Street Zen lowered KalVista Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Tuesday. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $32.60.
Get Our Latest Stock Analysis on KALV
About KalVista Pharmaceuticals
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
